We are excited to introduce the Bellevue Medical Group (BMG) as an early adopter of our Priority Access Program for Alzheimer’s patients! 🚀

Through this program, we are providing our personalized neurostimulators to selected neuro clinics for use in patients. 🧠

The BMG is a leading interdisciplinary network of:

• 60 experienced neurologists, neurosurgeons, and neuropsychologists
• 14 outpatient neurology centers
• 16 specialized outpatient clinics

Known for its cutting-edge diagnostics, personalized therapies, and sustainable, long-term care, BMG is the ideal partner for this initiative.

💡 Benefits of our Miamind® Neurostimulators:

• Personalized: Each device is tailored to the patient’s specific MRI data. The therapy plan is created after prescription and target region definition by the expert.
• Non-invasive: Transcranial stimulation (tCS) offers a safe, non-invasive alternative to treatments with reduced risks, according to current research.
• Scientifically backed: The benefits of tCS are grounded in extensive research and clinical studies.

Together with BMG, we are committed to improving access to innovative technologies and sustainably enhancing the quality of life for Alzheimer’s patients. A huge thank you to BMG for believing in our vision and partnering with us to drive progress in neurology. 🙌

📩 Please contact Bottneuro or the Bellevue Medical Group if you want to learn more about this pilot program.